RARA and acute promyelocytic leukemia: Resistance to the otherwise highly effective ATRA/ATO therapy makes it crucial to detect variant RARA gene partners in APL, especially since they are morphologically and immunophenotypically difficult to distinguish from the classic t(15;17)(q24.1;21.2) APL (PML::RARα gene fusion).9